Correspondence 0001214659-23-008791 from Biodexa Pharmaceuticals Plc (BDRX)
Biodexa Pharmaceuticals Plc
Date: June 23, 2023 · CIK: 0001643918 · Accession: 0001214659-23-008791
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-272693
Letter
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
June 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jason Drory
Re: Biodexa Pharmaceuticals Plc (the “Company”)
Registration Statement on Form F-1 (File No. 333-272693)
Originally Filed June 16, 2023
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act of 1933, as amended (the “Act”), the Company hereby respectfully requests that the Securities and Exchange Commission accelerates the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declares the Registration Statement effective as of 4:30 p.m., Washington D.C. time, on June 28, 2023, or as soon as practicable thereafter. In making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness by a telephone call to Alice Hsu at (212) 506-3634 of Orrick, Herrington & Sutcliffe LLP, and we request that such effectiveness also be confirmed in writing.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
Show Raw Text
CORRESP
1
filename1.htm
Biodexa Pharmaceuticals Plc
1 Caspian Point
Caspian Way
Cardiff, CF10 4DQ
United Kingdom
June 23, 2023
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
Attention: Jason Drory
Re:
Biodexa Pharmaceuticals Plc (the “Company”)
Registration Statement on Form F-1 (File No. 333-272693)
Originally Filed June 16, 2023
Ladies and Gentlemen:
Pursuant to Rule 461(a) under the Securities Act
of 1933, as amended (the “Act”), the Company hereby respectfully requests that the Securities and Exchange Commission accelerates
the effective date of the above-referenced Registration Statement on Form F-1 (the “Registration Statement”) and declares
the Registration Statement effective as of 4:30 p.m., Washington D.C. time, on June 28, 2023, or as soon as practicable thereafter. In
making this acceleration request, the Company acknowledges that it is aware of its responsibilities under the Act.
We request that we be notified of such effectiveness
by a telephone call to Alice Hsu at (212) 506-3634 of Orrick, Herrington & Sutcliffe LLP, and we request that such effectiveness also
be confirmed in writing.
Very truly yours,
BIODEXA PHARMACEUTICALS PLC
By: /s/ Stephen Stamp
Name:
Stephen Stamp
Title:
Chief Executive Officer & Chief Financial Officer
cc:
Alice Hsu, Esq., Orrick, Herrington & Sutcliffe LLP